NEW YORK, Sept. 21 – Qiagen executives on Friday warned  that third-quarter revenues are likely to fall 11 percent to $63 million as a result of disruptions following the Sept. 11 terrorist attacks in the United States.

Qiagen, which manufactures products for nucleic-acid purification, said it now expected to post third-quarter earnings of four cents a share, compared with a previous estimate of seven cents a share, the executives said in a conference call.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.